Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 4 Breast Neoplasms 4 Neoplasm Metastasis 3 Lung Neoplasms 3 Triple Negative Breast Neoplasms 2 Multiple Myeloma 2 Lymphoma 2 Glioblastoma 2 Colorectal Neoplasms 2 Stroke 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neurologic Manifestations 1 Myelodysplastic Syndromes 1 Motor Activity 1 Melanoma 1 Margins of Excision 1 Malignant Solid Neoplasm 1 Malignant Female Reproductive System Neoplasm 1 Localized Head and Neck Carcinoma 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Inflammatory Breast Neoplasms 1 Hematologic Neoplasms 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Depression 1 Communication 1

Interventions

pembrolizumab 57 Nivolumab 50 Ipilimumab 31 Specimen Handling 23 Magnetic Resonance Spectroscopy 19 Cyclophosphamide 14 Biopsy 11 fludarabine 10 binimetinib 10 Opdualag 10 trametinib 9 relatlimab 9 Radiosurgery 9 CTLA-4 Antigen 9 dabrafenib 8 lifileucel 7 fludarabine phosphate 7 aldesleukin 7 encorafenib 6 Interleukin-2 6 cemiplimab 5 atezolizumab 5 Paclitaxel 5 Blood Specimen Collection 5 X-Rays 4 Taxes 4 Pemetrexed 4 Gemcitabine 4 Cisplatin 4 Carboplatin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × Palliative Care × 90 days × Clear all

NCT02645149 2026-05-29

Match Mel

Melanoma Institute Australia

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡